QPCTL — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL484163	0.60	7/20
SCHEMBL2093317	0.58	7/20
SCHEMBL2093316	0.53	7/20
SCHEMBL2191343	0.61	6/20
SCHEMBL663206	0.41	6/20
SCHEMBL991449	0.58	5/20
SCHEMBL115966	0.51	4/20
Hydrochloric Acid (SCHEMBL2227020)	0.50	4/20
SCHEMBL1286648	0.46	4/20
SCHEMBL1193006	0.44	4/20
SCHEMBL1401382	0.42	4/20
SCHEMBL166982	0.65	3/20
SCHEMBL627763	0.62	3/20
SCHEMBL663096	0.61	3/20
SCHEMBL1799380	0.54	3/20
SCHEMBL2096521	0.46	3/20
Benzimidazole (SCHEMBL2338727)	0.46	3/20
SCHEMBL1875379	0.44	3/20
SCHEMBL621201	0.42	3/20
SCHEMBL621202	0.42	3/20

Clinical trials — most relevant to QPCTL by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From Real World	PHASE4	UNKNOWN
V-IMMUNE: A Novel Immunoglobulin Therapy for Immunodeficiency	PHASE3	RECRUITING
A Trial of CM-AT in Children With Autism With All Levels of FCT (The Blum Study)	PHASE3	COMPLETED
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders	PHASE2	COMPLETED
Wheat Flour Treatment With Microbial Transglutaminase and Lysine Ethyl Ester: New Frontiers in Celiac Disease Treatment.	PHASE2	UNKNOWN
Therapeutic Efficacy of L-Ornithine L-Aspartate Infusion in Patients With Acute Liver Failure	PHASE2	UNKNOWN
A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas	PHASE2	COMPLETED
Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus	PHASE2	COMPLETED
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers	PHASE1	COMPLETED
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine	EARLY_PHASE1	COMPLETED
Analysis by Clinical Mass Spectrometry of Bloodstains	nan	COMPLETED
Predictive Role of New Biomarkers for Hypersensitive Patients to Radiation in Breast Cancer (BIORISE)	nan	ACTIVE_NOT_RECRUITING
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation	nan	UNKNOWN
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
Choroid Plexus Dysfunction in Neurological Diseases	nan	RECRUITING
Effect of Dietary Amino Acid Profile on Lipoprotein Metabolism, Vascular Reactivity and Inflammatory Markers	nan	COMPLETED
A Study of the Interaction Between Tumor Susceptibility Gene Glycine N-methyltransferase (GNMT) and Lung Cancer	nan	UNKNOWN
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients	nan	COMPLETED
Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors	nan	COMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
The Glucagonotropic Effect of Amino Acids in Humans	nan	COMPLETED
Multiple Nutritional Deficiencies Causing Dementia of the Alzheimer Type	nan	UNKNOWN
Proteomic Pattern in Female Stress Urinary Incontinence: a Pilot Study	nan	COMPLETED
Regulation of Vitamin D Receptor (VDR),Calcium Sensing Receptor (CaSR), Cyclin D1,Ki67 and Proliferating Cell Nuclear Antigen (PCNA) in Primary Hyperparathyroidism	nan	UNKNOWN
Proteomic Profiling to Reveal Novel Prognostic Markers for Neurological Outcome Following Resuscitation	nan	COMPLETED
Dietary Interventions During Living Kidney Donations	nan	RECRUITING
Discovery of Soluble Biomarkers for Pancreatic Cancer Using Innovative All-Patient Inclusive Methodology	nan	RECRUITING
Establishing Radiolabelled PSMA as a Target for Glioma Treatment	nan	NOT_YET_RECRUITING
Comparison of Salivary and Crevicular Protein Concentrations of FIBA, PLMN, HEMO and ApoH in Healthy and Periodontitis Patients	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a QPCTL binder may also engage these)

Protein	Name	Similarity
Q4R942	—	0.999	Q4R942 →
Q0V8G3	—	0.992	Q0V8G3 →
Q8BH73	—	0.991	Q8BH73 →
GPAA1	GPI-anchor transamidase component GPAA1	0.965	landscape →
Q9UP52	—	0.961	Q9UP52 →
Q9WTK3	—	0.960	Q9WTK3 →
SMPD1	Sphingomyelin phosphodiesterase	0.960	landscape →
O97583	—	0.960	O97583 →
O09008	—	0.958	O09008 →
O00587	—	0.956	O00587 →
Q5IS64	—	0.955	Q5IS64 →
Q0VD19	—	0.955	Q0VD19 →
Q63148	—	0.954	Q63148 →
P52850	—	0.953	P52850 →
B2GUY2	—	0.952	B2GUY2 →
Q8IZ52	—	0.952	Q8IZ52 →
Q9JKX3	—	0.951	Q9JKX3 →
Q9P2E5	—	0.951	Q9P2E5 →
Q6IEE6	—	0.951	Q6IEE6 →
Q04519	—	0.951	Q04519 →
Q6IQX7	—	0.951	Q6IQX7 →
Q32M88	—	0.951	Q32M88 →
TRPM4	Transient receptor potential cation channel subfamily M member 4	0.950	landscape →
Q8HZR3	—	0.950	Q8HZR3 →
Q8N135	—	0.950	Q8N135 →
A6QM06	—	0.950	A6QM06 →
Q9Z0E2	—	0.950	Q9Z0E2 →
P52849	—	0.950	P52849 →
Q9EPI0	—	0.949	Q9EPI0 →
Q5STE3	—	0.949	Q5STE3 →